• DAMINENI SARITHA Department of Pharmaceutics, Sultan-ul-Uloom College of Pharmacy, Hyderabad-500034, Telangana State, India
  • P. SUBHASH CHANDRA BOSE Department of Pharmaceutics, MNR College of Pharmacy, Sangareddy, Telangana State, India
  • RIYAZ ALI M. OSMANI Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education and Research (JSSAHER), Mysuru-570015, Karnataka, India
  • PADMINI IRIVENTI Department of Pharmaceutics, Smt. Sarojini Ramulamma College of Pharmacy, Mahabubnagar- 509001, Telangana, India
  • SANDEEP KANNA Department of Pharmaceutics, Chalapathi Institute of Pharmaceutical Sciences, Guntur - 522034, Andhra Pradesh, India
  • GUNDAWAR RAVI Department of Pharmaceutical Quality Assurance, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal-576104, Karnataka, India



Haloperidol, Antipsychotic drug, BCS-II class of drugs, 32 factorial design


Objective: The main aim of the present study was to improve the dissolution rate of Haloperidol nanocrystals and thereby increase their bioavailability. Haloperidol is a typical antipsychotic drug and it is used to treat schizophrenia as well as acute mania and mixed states associated with bipolar disorder. Haloperidol falls into the Biopharmaceutics Classification System (BCS-II) class of drugs (poorly soluble aqueous and highly permeable) and has poor bioavailability.

Methods: The present study involves the preparation and optimization of Haloperidol nanocrystals by the anti-solvent precipitation method using Polaxomer407 and polyvinyl pyrrolidone K30 (PVP K30). The prepared nanocrystals were evaluated for various parameters like particle size, zeta potential, % drug content, % yield, surface morphology, drug-excipient compatibility studies (Fourier-transform infrared spectroscopy (FT-IR) and Differential Scanning Calorimetry (DSC)), and in vitro dissolution studies.

Results: Nine preparations were done and the best preparation amongst them was selected for further studies. F7 preparation containingpolaxomer407 and PVP K30 was selected as optimized preparation based on their evaluation parameters. 32 factorial design was used in the preparation. The particle size of the F7 nanocrystals was 300.2±2.7 nm and the zeta potential-36.3±3.2 mV. The % yield was in the range of 63.62±0.3%-98.21±0.8 %. The drug content of various preparations was found to be in the range of 58.46±0.8%-93.54±0.5 %. In vitro dissolution studies showed the highest % drug release for F7(91.54±0.03%) in 10 h.

Conclusion: F7 preparation was found to be having acceptable characteristics and thus selected as optimized preparation.


Download data is not yet available.


Shrivastava A, Aggarwal R, Singh RP, Khabiya R. A mini review on properties, mechanism of action, pharmacokinetic and pharmacodynamics and analytical methods of cariprazine. Int J App Pharm. 2023;15(1):31-5. doi: 10.22159/ijap.2023v15i1.46651.

Florence AT, Attwood D. Drug absorption and routes of administration. In: Physicochemical principles of pharmacy. 4th ed. London: Pharmaceutical Press; 2006. p. 329-91.

Dressman JB, Thelen K, Jantratid E. Towards quantitative prediction of oral drug absorption. Clin Pharmacokinet. 2008;47(10):655-67. doi: 10.2165/00003088-200847100-00003, PMID 18783296.

Sanjay B, Meena B. Nanocrystals: current strategies and trends. Int J Res Pharm Biomed Sci. 2012;3(1):407-19.

Tunick MH, Van Hekken DL, Cooke PH, Malin EL. Transmission electron microscopy of mozzarella cheeses made from microfluidized milk. J Agric Food Chem. 2002;50(1):99-103. doi: 10.1021/jf010633c, PMID 11754550.

Shegokar R, Muller RH. Nanocrystals: industrially feasible multifunctional formulation technology for poorly soluble actives. Int J Pharm. 2010;399(1-2):129-39. doi: 10.1016/j.ijpharm.2010.07.044, PMID 20674732.

Dong Y, Ng WK, Shen S, Kim S, Tan RB. Preparation and characterization of spironolactone nanoparticles by antisolvent precipitation. Int J Pharm. 2009;375(1-2):84-8. doi: 10.1016/j.ijpharm.2009.03.013, PMID 19481693.

Douroumis D, Fahr A. Stable carbamazepine colloidal systems using the cosolvent technique. Eur J Pharm Sci. 2007;30(5):367-74. doi: 10.1016/j.ejps.2006.12.003, PMID 17234395.

Kumar V, Wang L, Riebe M, Tung HH, Prud’homme RK. Formulation and stability of itraconazole and odanacatib nanoparticles: governing physical parameters. Mol Pharm. 2009;6(4):1118-24. doi: 10.1021/mp900002t, PMID 19366261.

Hu T, Wang J, Shen Z, Chen J. Engineering of drug nanoparticles by HGCP for pharmaceutical applications. Particuology. 2008;6(4):239-51. doi: 10.1016/j.partic.2008.04.001.

Kakran M, Sahoo NG, Li L, Judeh Z, Wang Y, Chong K. Fabrication of drug nanoparticles by evaporative precipitation of nanosuspension. Int J Pharm. 2010;383(1-2):285-92. doi: 10.1016/j.ijpharm.2009.09.030, PMID 19781606.

Tozuka Y, Miyazaki Y, Takeuchi H. A combinational supercritical CO2 system for nanoparticle preparation of indomethacin. Int J Pharm. 2010;386(1-2):243-8. doi: 10.1016/j.ijpharm.2009.10.044, PMID 19895877.

de Waard H, Grasmeijer N, Hinrichs WL, Eissens AC, Pfaffenbach PP, Frijlink HW. Preparation of drug nanocrystals by controlled crystallization: application of a 3-way nozzle to prevent premature crystallization for large-scale production. Eur J Pharm Sci. 2009;38(3):224-9. doi: 10.1016/j.ejps.2009.07.005, PMID 19631270.

Tugba G, Neslihan RG, Leven T. Nanocrystal technology for oral delivery of poorly water-soluble drugs. Fabad J Pharm Sci. 2010;34:55-65.

Xia D, Quan P, Piao H, Piao H, Sun S, Yin Y. Preparation of stable nitrendipine nanosuspensions using the precipitation-ultrasonication method for enhancement of dissolution and oral bioavailability. Eur J Pharm Sci. 2010;40(4):325-34. doi: 10.1016/j.ejps.2010.04.006, PMID 20417274.

Sinha B, Muller RH, Moschwitzer JP. Bottom-up approaches for preparing drug nanocrystals: formulations and factors affecting particle size. Int J Pharm. 2013;453(1):126-41. doi: 10.1016/j.ijpharm.2013.01.019, PMID 23333709.

Gao L, Liu G, Ma J, Wang X, Zhou L, Li X. Drug nanocrystals: in vivo performances. J Control Rel. 2012;160(3):418-30. doi: 10.1016/j.jconrel.2012.03.013.

Anju G, Rupa M, Kamla P. Formulation, optimization and characterization of ziprasidone nanocrystals prepared by media milling method. Int J Pharm Sci. 2015;7(8):146-50.

Wei L, Ji Y, Gong W, Kang Z, Meng M, Zheng A. Preparation, physical characterization and pharmacokinetic study of paclitaxel nanocrystals. Drug Dev Ind Pharm. 2015;41(8):1343-52. doi: 10.3109/03639045.2014.950272, PMID 25156484.

Du B, Shen G, Wang D, Pang L, Chen Z, Liu Z. Development and characterization of glimepiride nanocrystal formulation and evaluation of its pharmacokinetic in rats. Drug Deliv. 2013;20(1):25-33. doi: 10.3109/10717544.2012.742939, PMID 23311650.

Arun K, Rajkumar M, Anil B. Design, development and evaluation of nanocrystals of valsartan for solubility enhancement. World J Pharm Pharm Sci. 2014;3(3):1414-27.

Shah SR, Parikh RH, Chavda JR, Sheth NR. Glibenclamide nanocrystals for bioavailability enhancement: formulation design, process optimization, and pharmacodynamic evaluation. J Pharm Innov. 2014;9(3):227-37. doi: 10.1007/s12247-014-9189-y.

Abdullah NA, Jufri M, Munim A, Saputri FC. Celastrol nanoemulgel formulation and in vitro penetration test. Int J Pharm Pharm Sci 2020;12(8):82-91. doi: 10.22159/ijpps.2020v12i8.37167.

Taheri A, Soltanpour S, Bastami Z. Formulation, optimization and characterization of gemfibrozil nanocrystals prepared by wet milling technique. Asian J Pharm. 2015;9(1):19-22. doi: 10.4103/0973-8398.150032.

Jiang T, Han N, Zhao B, Xie Y, Wang S. Enhanced dissolution rate and oral bioavailability of simvastatin nanocrystal prepared by sonoprecipitation. Drug Dev Ind Pharm. 2012;38(10):1230-9. doi: 10.3109/03639045.2011.645830, PMID 22229827.

Alhamhoom Y, Ravi G, Osmani RAM, Hani U, Prakash GM. Formulation, characterization, and evaluation of eudragit-coated saxagliptin nanoparticles using 3 factorial design modules. Molecules. 2022;27(21):1-17. doi: 10.3390/molecules27217510, PMID 36364338.

Paun JS, Tank HM. Screening of formulating and processing parameters for ziprasidone hydrochloride nanosuspension prepared by nanoprecipitation ultrasonication technique. J Pharm Sci Biosci Res. 2016;6(6):766-72. doi: 10.13286/j.1001-5213.2021.14.09.

Gautham U, Patil A, Hemanth G. Formulation and evaluation of nanoparticle drug delivery system for treatment of hypertension. Int J App Pharm. 2023;15(6):90-7. doi: 10.22159/ijap.2023v15i6.48971.

Garg S, Pareek PP, Trivedi S, Puri D, Saini PCS, Ajay CS. Formulation and evaluation of fast-dissolving tablet of ziprasidone HCl. Indo Am J Pharm Res. 2013;3(5):3642-51.

Bhujbal NS, Karthickeyan K. Formulation and development of nanocrystals by using natural amino acid. Eur Chem Bull. 2023;12(3):861-72. doi: 10.31838/ecb/2023.12.3.064.

Louis D. Formulation and evaluation of nanocrystals of a lipid-lowering agent. Iran J Pharm Res. 2016;15(1):71-82, PMID 27610148.

Ravi G, Gupta NV. Development and evaluation of transdermal film containing solid lipid nanoparticles of rivastigmine tartrate. Int J App Pharm. 2017;9(6):85-90. doi: 10.22159/ijap.2017v9i6.22354.

Aya ME. NagiaAEl-M, Hanan Mel-N. Formulation and evaluation of fast-dissolving tablets of haloperidol solid dispersion. Saudi Med J. 2022;30:1589-602. doi: 10.1016/j.jsps.2022.09.002.

Sharma A, Jain AP, Arora S. Formulation and in vitro evaluation of nanocrystal formulation of poorly soluble drugs. J Drug Delivery Ther. 2019;9(4-s):1183-90. doi: 10.22270/jddt.v9i4-s.3873.



How to Cite




Original Article(s)